Ablation of the remnant thyroidal tissue by radioactive iodine (RAI) is a well-established adjuvant treatment for differentiated thyroid carcinoma, though
its effectiveness has been questioned for surgically curable diseases.
1
Recent guidelines as well as other proposals recommend selective use of RAI ablation,
considering both the clinical and the histopathologic characteristics of each patient.
2
,
3
,
British Thyroid Associations & Royal College of Physicians. Guidelines for the management of thyroid cancer in adults. 2nd ed. 2007. Available from: www.british-thyroid-association.org
4
,
NCCN Clinical Practice Guidelines in Oncology. Thyroid Carcinoma (2009 v1). Available from: http://www.nccn.org/professionals/physician_gls/PDF/thyroid.pdf
5
In fact, management of patients with differentiated thyroid carcinoma (ie, the extent
of surgery and adjuvant therapy) has been controversial, particularly for low-risk
patients, even in the United States.
6
,
- Hundahl S.A.
- Cady B.
- Cunningham M.P.
- Mazzaferri E.
- McKee R.F.
- Rosai J.
- et al.
Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma
treated in the United States during 1996. U.S. and German Thyroid Cancer Study Group
An American College of Surgeons Commission on Cancer Patient Care Evaluation study.
An American College of Surgeons Commission on Cancer Patient Care Evaluation study.
Cancer. 2000; 89: 202-217
7
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer.Endocrinol Metab Clin North Am. 2008; 37: 457-480
- American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.Thyroid. 2006; 16 (Available from): 109-142
British Thyroid Associations & Royal College of Physicians. Guidelines for the management of thyroid cancer in adults. 2nd ed. 2007. Available from: www.british-thyroid-association.org
NCCN Clinical Practice Guidelines in Oncology. Thyroid Carcinoma (2009 v1). Available from: http://www.nccn.org/professionals/physician_gls/PDF/thyroid.pdf
- Medical management of thyroid cancer: a risk adapted approach.J Surg Oncol. 2008; 97: 712-716
- An American College of Surgeons Commission on Cancer Patient Care Evaluation study.Cancer. 2000; 89: 202-217
- Is total thyroidectomy the best possible surgical management for well-differentiated thyroid cancer?.Lancet Oncol. 2005; 6: 529-531
- Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma.Surgery. 2010; 147: 424-431
- Nationwide survey on the treatment policy for well-differentiated thyroid cancer — results of a questionnaire distributed at the 37th meeting of the Japanese Society of Thyroid Surgery.Endocr J. 2005; 52: 479-491
- A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during follow-up period.Surgery. 2004; 135: 139-148
Article info
Publication history
Accepted:
November 20,
2009
Identification
Copyright
© 2010 Mosby, Inc. Published by Elsevier Inc. All rights reserved.
